{"entity":{"id":"men1703","kind":"drug","name":"MEN1703","aka":["Dapolsertib hydrochloride"],"tldr":"MEN1703 is an experimental small molecule (kinase inhibitor) from Ryvu Therapeutics in phase 2 trials for hodgkin lymphoma, aimed at FLT3.","summary":"MEN1703 (SEL24) is a small molecule (kinase inhibitor) developed by Ryvu Therapeutics. Its target is FLT3 (the sponsor names PIM/FLT3 kinase). ClinicalTrials.gov describes the intervention as: MEN1703 (Dapolsertib hydrochloride) is a potent dual inhibitor of proviral integration site for Moloney murine leukaemia virus (PIM) kinases and Fms-like tyrosine kinase 3 (FLT3). It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, in hodgkin lymphoma. The largest, NCT06534437, plans to enrol 178 participants with primary completion expected 2026-12. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.","status":"phase-2","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov: trials of MEN1703","url":"https://clinicaltrials.gov/search?intr=SEL24"},{"label":"Sponsor page","url":"https://www.ryvu.com"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["hodgkin-lymphoma"],"sections":[],"technologies":[],"targets":["flt3"],"drugs":[],"companies":["ryvu-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":["nct06534437"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor pipeline pages)","editedOn":"2026-09-11"},"code":"SEL24","modality":"small molecule (kinase inhibitor)","mechanism":"Small molecule (kinase inhibitor) directed at FLT3, as stated in the ClinicalTrials.gov intervention record; the detailed mechanism is not stated.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/men1703/","neighbours":{"cancer":[{"id":"hodgkin-lymphoma","kind":"cancer","name":"Hodgkin lymphoma","route":"/cancers/hodgkin-lymphoma/"}],"target":[{"id":"flt3","kind":"target","name":"FLT3","route":"/targets/flt3/"}],"company":[{"id":"ryvu-therapeutics","kind":"company","name":"Ryvu Therapeutics","route":"/companies/ryvu-therapeutics/"}],"trial":[{"id":"nct06534437","kind":"trial","name":"MEN1703 (SEL24) to Treat Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma (JASPIS-01)","route":"/trials/nct06534437/"}]}}